

# Endocrine Dysfunction in Prader-Willi Syndrome: A Review with Special Reference to GH

PIA BURMAN, E. MARTIN RITZÉN, AND ANN CHRISTIN LINDGREN

Pharmacia Corporation, SE-112 87 Stockholm, Sweden (P.B.) and Department of Woman and Child Health, Karolinska Institute, SE-171 76 Stockholm, Sweden (E.M.R., A.C.L.)

Prader-Willi syndrome is a genetic disorder occurring in 1 in 10,000–16,000 live-born infants. In the general population, approximately 60 people in every 1,000,000 are affected. The condition is characterized by short stature, low lean body mass, muscular hypotonia, mental retardation, behavioral abnormalities, dysmorphic features, and excessive appetite with progressive obesity. Furthermore, morbidity and mortality are high, probably as a result of gross obesity. Most patients have reduced GH secretory capacity and hypogonadotropic hypogonadism, suggesting hypothalamic-pituitary dysfunction. Replacement of GH and/or sex hormones may therefore be beneficial in Prader-Willi syndrome, and several clinical trials have now evaluated GH replacement therapy in affected

children. Results of GH treatment have been encouraging: improved growth, increased lean body mass, and reduced fat mass. There was also some evidence of improvements in respiratory function and physical activity. The long-term benefits of GH treatment are, however, still to be established. Similarly, the role of sex hormone replacement therapy needs to be clarified as few data exist on its efficacy and potential benefits. In summary, Prader-Willi syndrome is a disabling condition associated with GH deficiency and hypogonadism. More active treatment of these endocrine disorders is likely to benefit affected individuals. (*Endocrine Reviews* 22: 787–799, 2001)

- I. Introduction
  - A. A brief description of the syndrome
  - B. Body composition in patients with Prader-Willi syndrome
  - C. Prognosis
- II. GH Secretory Status in Patients with Prader-Willi Syndrome
- III. The Hypothalamic-Pituitary-Gonadal Axis and Sexual Development in Prader-Willi Syndrome
- IV. The Status of Other Hormonal Axes in Prader-Willi Syndrome
- V. Endocrine Treatment of Patients with Prader-Willi Syndrome
  - A. Effects of GH treatment on stature
  - B. Effects of GH treatment on body composition and muscle function
  - C. Other effects of GH treatment
  - D. Side effects of GH treatment
  - E. Sex hormone replacement therapy
- VI. Summary

## A. A brief description of the syndrome

Prader-Willi syndrome is a genetic disorder characterized by both mental and physical abnormalities. Occurring in 70–75% of affected individuals, the principal genetic mutation associated with the condition is deletion of a segment of the paternally derived chromosome 15 (15q11-q13). Several other abnormalities have also been linked with the syndrome: 20–25% of patients exhibit maternal disomy of the same region of chromosome 15, 2–5% have imprinting center mutations, and 1% have translocations (3–5). The individual gene or genes from within 15q11-q13 that cause the condition have yet to be identified. More detailed reviews of the genetics associated with Prader-Willi syndrome are given by Cassidy (4) and Nicholls *et al.* (6).

Clinically, Prader-Willi syndrome is characterized by a range of mental and physical symptoms. These include short stature, muscular hypotonia, excessive appetite with progressive obesity, hypogonadism, mental retardation, behavioral abnormalities, sleep disturbances (including sleep apnea), and dysmorphic features (7, 8). The photograph of a boy with Prader-Willi syndrome illustrates the typical physical features of the condition (Fig. 1). Diagnosis of Prader-Willi syndrome is made according to a set of consensus clinical criteria that were published in 1993 (Table 1). On this basis, it is estimated that one child in every 10,000–25,000 live births suffers from the syndrome (9–11). However, as diagnosis relies on subjective identification of characteristic symptoms and signs, it is likely that this figure is not completely accurate. More recent studies of “at-risk” populations, including newborns, suggest that the prevalence is likely to be around 1:15,000, ranging from 1:10,000–1:16,000 (4, 12, 13). Mass screening for distinctive genetic abnormalities in the 15q11-q13 chromosomal region would enable a

## I. Introduction

SINCE PRADER-WILLI SYNDROME was first described around 45 yr ago (1, 2), there has been interest in the endocrine aspects of the condition. Recent years, however, have seen a growth of interest in this area; therefore, in this review we aim to provide a thorough analysis of endocrine dysfunction in Prader-Willi syndrome and give a full account of the therapeutic options available.

Abbreviations: BMI, Body mass index; DEXA, dual energy x-ray absorptiometry; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; GHD, GH deficiency; LBM, lean body mass.




FIG. 1. A typical 11-yr-old boy with Prader-Willi syndrome. He is short for his age, has central obesity, low muscular mass, cryptorchidism, and typical facial feature with narrow bifrontal diameter, almond shaped eyes, small appearing mouth with thin upper lip, and down turned corners of mouth. In addition, his hands and feet are small. [Reproduced with permission.]

“true” prevalence to be calculated, but a study of this nature would not be cost effective. To date, screening of high-risk populations (12) remains the most efficient method of identifying patients with Prader-Willi syndrome.

In the newborn child, Prader-Willi syndrome first manifests as muscular hypotonia. It is often so pronounced that babies are described as “floppy.” They frequently have feed-

TABLE 1. Clinical diagnostic criteria for Prader-Willi syndrome

Major criteria (1 point each)	
Neonatal and infantile hypotonia	
Infantile feeding problems or failure to thrive	
Excessive or rapid weight gain between the ages of 1 and 6 yr	
Characteristic facial features, including narrow face, almond-shaped eyes, small-appearing mouth with thin upper lip, down-turned corners of the mouth (three or more required)	
Hypogonadism (impaired function of the gonads) with underdeveloped genitalia and/or impaired pubertal development	
Developmental delay, mental retardation, or learning problems	
Hyperphagia, food foraging, or obsession with food	
Deletion 15q11-q13 on high-resolution cytogenetic analysis or other abnormality of the Prader-Willi chromosome region	
Minor criteria (0.5 points each)	
Decreased fetal movement or infantile lethargy	
Typical behavioral problems: temper tantrums, violent outbursts; obsessive/compulsive behavior, argumentative, rigid, possessive, stubborn manipulative, stealing, lying (five or more required)	
Sleep disturbances or sleep apnea	
Short stature for family by the age of 15 yr	
Fairer eyes, skin, and hair than expected	
Smaller hands and feet than expected for height and age	
Narrow hands with straight ulnar border	
Esotropia or myopia	
Viscous saliva	
Speech articulation defects	
Skin picking	
Supportive criteria (0 points, but help to confirm diagnosis)	
High pain threshold	
Reduced incidence of vomiting	
Temperature control problems	
Scoliosis or kyphosis	
Early adrenarche	
Osteoporosis	
Unusual skill with jigsaw puzzles	
Normal neuromuscular findings	

Five points ( $\geq 4$  points from major criteria) strongly suggest Prader-Willi syndrome in children  $\leq 3$  yr old, whereas 8 points ( $\geq 5$  points from major criteria) are indicative in older individuals. [Adapted with permission from *Pediatrics*, Vol. 91, page(s) 398–402, Table 1, © 1993 (8).]

ing difficulties due to poor suck and thus require tube feeding for several weeks or months (7, 9).

Children with Prader-Willi syndrome usually become overweight by the age of 4 yr as a consequence of their insatiable appetite and compulsive eating (14). Unfortunately, obesity progresses with age (15–17), and historically we have observed that about one-third of individuals with Prader-Willi syndrome are more than twice their ideal body weight (18, 19). Obesity is a risk factor for many other serious conditions, including cardiovascular disease and diabetes; hence, it is a major cause of increased morbidity and mortality among patients with Prader-Willi syndrome (20, 21).

Restriction of growth is also a frequently observed sequel of Prader-Willi syndrome: approximately 90% of affected individuals are short in stature (9). This problem is illustrated by a study in which the weight and height of 71 Caucasian Americans, aged 4–24 yr, with Prader-Willi syndrome were compared with healthy subjects. The 50<sup>th</sup> centile for height in the patient group fell below the normal 5<sup>th</sup> centile by the age of 12–14 yr, whereas the 50<sup>th</sup> centile for weight in the affected individuals approximated the 95<sup>th</sup> centile in the healthy pop-

ulation (22). As a result of their feeding difficulties, affected infants often fail to thrive and, during the first year, this may result in growth below the 3<sup>rd</sup> percentile. Thereafter, linear growth is only slightly compromised, remaining at the 10<sup>th</sup> percentile or below until the age of 10 yr for females and 12 yr for males. After this time, height velocity often declines relative to the norm at these ages, due to a lack of growth spurt (9, 22). This growth pattern may vary in the individual child, partly as a consequence of evolving obesity or dietary interventions. Thus, it is not uncommon to see temporary growth arrest when caloric restrictions take effect after late diagnosis, or, conversely, an improvement in growth rate may be seen when obesity develops. Cassidy (4) reported that the mean adult heights achieved by men and women with Prader-Willi syndrome were 155 and 148 cm, respectively. Wollmann *et al.* (16), however, found that mean height was slightly higher at 162 and 150 cm for men and women, respectively, while Hauffa and colleagues (23) noticed a near final mean height of 159 cm in boys and 149 cm in girls. Nagai and co-workers (24) constructed growth curves for Japanese children with Prader-Willi syndrome and found that mean final height was approximately 141 cm in girls and 148 cm in boys. These values are considerably below  $-2$  SD scores for healthy Japanese individuals.

During their first 6 yr of life, children with Prader-Willi syndrome often do not achieve normal levels of cognitive, motor, and language development. Indeed, according to one study, these individuals have a below-average IQ of about 70 (25). A review of cognitive ability among 575 affected individuals confirms this, showing that just 5% of patients had a normal IQ (*i.e.*,  $> 85$ ) (26). Borderline mental retardation was observed in 28% of patients, while 34%, 27%, and 5%, respectively, were mildly, moderately, or severely mentally retarded. In addition to impaired mental development, many sufferers of Prader-Willi syndrome display a range of behavioral problems (4). As mentioned earlier, these include excessive appetite and lack of food selectivity, but there is also a high incidence of stubbornness, verbal perseverance, skin picking, and temper tantrums. Furthermore, affected individuals have a tendency toward depression and a diminished ability to initiate and maintain social contacts. A high pain threshold is also characteristic of the condition, and sleep apnea and excessive daytime sleepiness are particularly common among older children. Given these problems it is not surprising that many children with Prader-Willi syndrome experience learning disabilities and often require special education services (8).

The handicaps associated with Prader-Willi syndrome have significant implications in later life, as many of those affected are incapable of independent living. According to a large survey of adults with the condition (20), the majority lived in group homes or with their family. More than one-third (35%) did not work; of those who did work, the vast majority were employed in a sheltered environment. There was still a high incidence of behavioral problems, and hospital admissions due to physical or psychiatric problems were frequent. The author reported that the identified aberrant behaviors resulted from the physical aspects of the syndrome, *i.e.*, the relentless hunger and the psychosocial pressures of being obese, sexually immature, and cognitively limited.

### B. Body composition in patients with Prader-Willi syndrome

Prader-Willi syndrome is associated with high body fat mass and low muscle mass. Accurate determination of body composition is, therefore, an important aspect of monitoring both the progression of the condition and its treatment. Bioelectrical impedance analysis (which separates fat-free mass from fat mass), skinfold thickness (in which sc fat mass at various locations is recorded), and dual energy x-ray absorptiometry (DEXA, which provides a measure of fat tissue, bone, and non-bone lean mass) are the most widely used methods of assessing body composition. Bioelectrical impedance analysis, however, may be inadequate to measure changes in body composition in Prader-Willi syndrome because the ratio of lean to fat mass is decreased, requiring a special adaptation of mathematical estimates (27). For healthy subjects, DEXA is presently regarded as the “gold standard” because it allows different regions of the body to be assessed, and fat, bone, and lean mass are directly visualized and calculated. Further research is required, however, to determine whether it is worthy of the same status in Prader-Willi syndrome. One of the main limitations of DEXA and, indeed, of other methods, is that muscle mass can only be deduced indirectly, as the “lean mass” parameter comprises both water and cellular components. Accurate evaluation of muscle mass requires additional investigations, such as assessment of total potassium and/or extracellular water mass.

Despite their inherent limitations, data from the above methods have been found to correlate with each other. All three techniques and the “weight for height” method have also consistently confirmed distinct differences in the body composition of patients with Prader-Willi syndrome when compared with healthy controls. For example, in three studies involving young individuals affected with the condition, the mean percent body fat was 42% [ $n = 14$  (28)], 51% [ $n = 5$  (29)], and 47% [ $n = 27$  (15)]. In contrast, in a population of 403 healthy Dutch individuals aged 4–20 yr, mean percent body fat was only 11% in males, 15.5% in girls less than 15 yr old, and 24% in females older than 15 yr (30). Similar results have been reported in an Australian study involving 265 healthy individuals aged 4–26 yr, with percent body fat ranging from 4.8% to 34.1% (median, 14.4%) in males and from 10.4% to 47.7% (median, 22.8%) in females (31).

Recently, Brambilla and co-workers (15) used DEXA to show that patients with Prader-Willi syndrome had a low lean body mass (LBM) as well as a higher ratio of fat mass to LBM compared with both healthy individuals of normal weight and, importantly, those with simple obesity (Fig. 2). The study also suggested that LBM declines further with age. Young children with Prader-Willi syndrome ( $< 12$  yr old) had an LBM that was 81–93% of that found in the children of normal weight, whereas in older patients LBM was only 63–83% of the normative values. Limb areas appeared to be most compromised. In addition, bone mineral content was found to be lower than in the healthy obese and normal weight populations. Notably, Eiholzer and co-workers (32) have shown that, even in the first years of life, children with Prader-Willi syndrome have an abnormally low LBM.




FIG. 2. The ratio of fat mass to lean mass in 27 patients (10 who were younger than 12 yr) with Prader-Willi syndrome (mean age, 14.2  $\pm$  5.1 yr; mean BMI, 27.1  $\pm$  6.6 kg/m<sup>2</sup>), 27 obese healthy individuals (mean age, 13.7  $\pm$  4.1 yr; mean BMI, 29.7  $\pm$  5.4 kg/m<sup>2</sup>), and 27 healthy individuals of normal weight (mean age, 13.7  $\pm$  4.1 yr; mean BMI, 18.7  $\pm$  2.7 kg/m<sup>2</sup>). Values are mean  $\pm$  SD. \*,  $P < 0.05$  compared with normal weight group; \*\*,  $P < 0.05$  compared with obese group. [Reproduced with permission from: P. Brambilla *et al.*: *Am J Clin Nutr* 65:1369–1374, 1997 (15). © American Society for Clinical Nutrition.]

The low LBM associated with Prader-Willi syndrome is likely to reflect a reduced muscle mass, and thus it may contribute to the observed moderate clinical hypotonia and poor physical performance of these individuals (15, 33). Muscle is a metabolically active tissue, and a small mass of this tissue, in conjunction with reduced physical activity (28), explains the low energy expenditure found in patients with Prader-Willi syndrome (34–37). In one study, patients with the condition expended approximately 50% less energy than healthy obese controls (18).

### C. Prognosis

Prader-Willi syndrome is associated with increased morbidity and premature mortality, the main cause of which is thought to be obesity (20, 21). Many of the medical complications of obesity, including type II diabetes mellitus, hypertension, atherosclerosis, hyperlipidemia, compromised cardiopulmonary function, sleep disturbance, and psychological problems, such as depression and lack of self-esteem (38–42), have also been described in Prader-Willi syndrome. Affected individuals are also at risk of developing scoliosis, and this may be a concern when considering GH therapy to improve growth rate. Up to 80% of patients are reported to have a scoliosis exceeding 10°, and 15–20% have clinically significant scoliosis (43). Similarly, the incidence of osteoporosis is higher among patients with Prader-Willi syndrome, to which reduced GH secretion and hypogonadism could contribute (44). Lastly, given their high risk of comorbidity, mental retardation, lack of employment, and limited social and personal relationships, poor quality of life is a major concern for patients with Prader-Willi syndrome (4, 25, 38).

It should be noted, however, that most studies of comor-

bidity in Prader-Willi syndrome have suffered from limited patient samples and lack of appropriate control groups. In addition, many of these reports date from a period when restricted caloric intake and training of eating habits were not widely accepted control strategies. The literature on this aspect of the disease must therefore be interpreted with care, and high quality epidemiological studies are awaited. In the following sections we review the current literature pertaining to three of the most significant comorbid conditions in Prader-Willi syndrome: glucose intolerance, vascular disease, and respiratory disease.

**1. Glucose tolerance.** A number of reports suggest that glucose tolerance is abnormal in individuals with Prader-Willi syndrome. Fasting plasma insulin concentration and the insulin response to glucose are often increased in affected individuals, suggesting insulin resistance (45). A reduction in the number of insulin receptors on monocytes has also been described in the syndrome, echoing a similar abnormality seen in patients with simple obesity (46).

The reported prevalence of diabetes mellitus among patients with Prader-Willi syndrome varies. For example, Hall and Smith (17) found that 5 of 14 children with Prader-Willi syndrome had diabetic glucose tolerance and one had diabetes. Similarly, Illig and co-workers (47) reported that 41% of affected patients 15 yr of age and younger ( $n = 34$ ) had reduced glucose tolerance, of which 21% had diabetes. Diabetes is also common in older patients. In a study involving 23 patients aged 15–41 yr, 17% had diabetes mellitus, the majority of whom required insulin therapy (21). A high incidence of type II diabetes mellitus in adults with Prader-Willi syndrome was also shown by Cassidy *et al.* (48), who studied 22 individuals aged 30–55 yr over a period of 1–12 yr. Nine of the patients (41%) developed diabetes mellitus. Clinically, the diabetes presented as type II, which responded to weight reduction and oral hypoglycemic agents. Finally, in one of the largest surveys to date, the prevalence of diabetes was lower than that described by Cassidy and co-workers. Of 232 adults with Prader-Willi syndrome (age, 16–64 yr), 44 (19%) had diabetes, 29 of whom required insulin (20).

The differing rates of diabetes reported by these authors could result from differences in age and body weight between the study groups. In most of the above studies, however, a large proportion of patients were grossly obese.

In contrast to these reports, some recent studies involving children with Prader-Willi syndrome who were of normal weight or only moderately obese have demonstrated low insulin levels combined with normal serum glucose concentrations (49–52). As subjects with “simple” obesity generally have elevated insulin levels, these results suggest that patients with Prader-Willi syndrome have increased insulin sensitivity, which is different from that of the grossly obese. One interpretation of these findings would be that some degree of GH insufficiency in Prader-Willi syndrome increases insulin sensitivity. Additionally, the high prevalence of diabetes cited in earlier reports may be secondary to gross obesity rather than a feature of the syndrome itself, but this is an area in which more data are needed.

2. *Vascular disease.* Patients with Prader-Willi syndrome appear to be at high risk of vascular disease. For example, Cassidy and co-workers (48) found that as many as 32% of patients with the condition were hypertensive ( $n = 22$ ). A lower prevalence of hypertension (17%), however, was observed in a larger-scale survey (20), during which one man experienced a stroke at the age of 24 yr. Again, this study showed that comorbidity was related to weight gain, as hypertension, heart problems, and respiratory difficulties were all correlated with obesity. Several other cases of vascular disease in Prader-Willi syndrome exist in the literature. Advanced coronary atherosclerotic disease, for example, has been described in two patients who were less than 35 yr old (53, 54). One of the original patients described by Prader and co-workers (1) died at the age of 28 yr after developing diabetic vascular complications (55), and a 26-yr-old patient with Prader-Willi syndrome was recently reported to have experienced silent myocardial infarction and hyperlipidemia. The same patient also had rapidly progressive diabetic retinopathy and neuropathy (56). The authors suggested that premature atherosclerotic coronary disease might play an unrecognized role in mortality and morbidity associated with Prader-Willi syndrome. However, their conclusion is based solely on case reports, and controlled data are required before a firm link can be made. Hyperlipidemia may also be a feature of Prader-Willi syndrome, although both normal and elevated lipid levels have been reported (57–60). In a study by l'Allemand and colleagues, 25% of children with Prader-Willi syndrome had elevated levels of low-density lipoprotein cholesterol and apolipoprotein B (61).

3. *Respiratory disease.* Impaired respiratory function is frequently observed in patients with Prader-Willi syndrome (62). Cassidy and colleagues (48) found that seven of eight affected individuals over the age of 30 yr had restrictive lung disease, and Laurance *et al.* (21) reported that cor pulmonale was the most common cause of death among nine patients with the condition. A further complication seen in affected patients with reduced lung function is hypercapnia (62). Until recently, this was thought to be a secondary effect of respiratory muscle weakness or the result of Pickwickian syndrome brought about by increased abdominal and thoracic fat. However, we and other investigators have now found that affected individuals have an impaired response to short periods of hypercapnia and a reduced ventilatory volume, indicating that the sensitivity of peripheral chemoreceptors to changes in blood oxygen and carbon dioxide is decreased (63–65). Thus, it seems that impaired respiratory function in Prader-Willi syndrome is not caused solely by obesity or muscle weakness.

## II. GH Secretory Status in Patients with Prader-Willi Syndrome

There are many data indicating reduced GH secretion in patients with Prader-Willi syndrome. Low peak GH response to stimulation tests, decreased spontaneous GH secretion, and low serum IGF-I levels have been documented in at least 15 studies involving about 300 affected children

(Table 2 and Refs. 49, 60, 66–78). Depending on the stimulation test used, 40–100% of children with this condition fulfill the criteria for GH deficiency (GHD), which is generally defined as peak GH levels of less than 10  $\mu\text{g}/\text{liter}$  in response to one or two stimulation tests. The majority of affected children also have low GH secretion when measured by frequent blood sampling over 24 h. However, healthy, obese individuals also show reduced GH secretion during provocation tests, when compared with healthy, “lean” controls (79). The cause of reduced GH secretion in obesity is not fully understood and both FFA (80) and insulin have been proposed as mediators of this effect (81). At least one study has shown elevated levels of free IGF-I in individuals with “simple” obesity, suggesting a negative feedback at the pituitary/hypothalamic level (82). However, normal levels of free IGF-I have been found in other studies of subjects with the same condition (83). As a result of these findings, it has been argued that the apparent GH insufficiency in patients with Prader-Willi syndrome simply reflects their obesity. To determine whether this is in fact the case, a detailed comparison of the two conditions with respect to GH-related parameters and clinical features is required.

Firstly, the GH response to GHRH in obese individuals is enhanced by simultaneous administration of a cholinesterase inhibitor, such as pyridostigmine (84). This effect is probably the result of reducing somatostatinergic tone. In contrast, when these agents are coadministered to patients with Prader-Willi syndrome, 13 of 18 still showed a blunted GH response, suggestive of genuine GHD (85). In children with GHD and most, but not all, children with Prader-Willi syndrome (Table 2), serum IGF-I levels are reduced, whereas healthy children with simple obesity have normal or slightly elevated IGF-I levels. Furthermore, the level of IGF-I has been shown to correlate with body mass index (BMI) in obese children (83, 86). This is not the case in children with Prader-Willi syndrome (77), where low IGF-I and GH levels are not limited to those who are severely obese but have also been found in patients who are of normal weight. Lastly, in contrast to healthy obese children (80, 83, 87), depressed levels of IGF-binding protein 3 have been reported in affected individuals (49).

Clinical features of the condition also support the presence of GHD in Prader-Willi syndrome. Both Prader-Willi syndrome and GHD are characterized by short stature, obesity with extra fat deposits over the abdomen, abnormal body composition with reduced muscle mass and decreased bone density, and, in some patients, retarded bone age (8, 16, 88). Conversely, children with simple obesity are often tall for their age and have an increased absolute fat free mass and advanced bone age (89, 90). In summary then, available data suggest that, as a group, patients with Prader-Willi syndrome are GH deficient, although the degree of GHD may vary from mild to severe insufficiency.

The occurrence of reduced GH secretion and hypogonadotropic hypogonadism (see *Section III*) in the majority of children with Prader-Willi syndrome, together with abnormal appetite control and high pain threshold, suggest hypothalamic-pituitary dysfunction. Autopsies of five patients with Prader-Willi syndrome performed by Swaab and co-workers (91) indicated that the paraventricular nucleus was

TABLE 2. Summary of studies assessing GH status in children with Prader-Willi syndrome

Authors, year (ref.)	No. of patients (age in years)	Methods	Results
Fessler and Bierich, 1983 (66)	12 children	Arginine stimulation test, GHD = peak GH < 10 $\mu\text{g/liter}$	GHD in 7/12 (58%)
Costeff <i>et al.</i> , 1990 (67)	6 (8–11), 5 were of normal wt	Clonidine stimulation test; 24-h GH secretion; somatomedin-C levels	Peak GH response to clonidine below reference range in 4/6; mean GH secretion below reference range in 6/6; somatomedin-C levels in lower reference age in 6/6
Calisti <i>et al.</i> , 1991 (68)	5 (5–12)	Insulin tolerance test and L-dopa stimulation tests; GHD = peak GH < 10 $\mu\text{g/liter}$	Low peak GH in both tests in 2/5
Huw <i>et al.</i> , 1992 (69)	11 (8.8 $\pm$ 1.2)	Sequential clonidine and arginine test, GHD = peak GH < 10 $\mu\text{g/liter}$ ; IGF-I levels	GHD in 10/11 (91%); IGF-I mean SD score, $-1.9 \pm 1.3$
Cappa <i>et al.</i> , 1993 (70)	10 (6–24); 8 obese controls (6–12); 9 short healthy controls (8–13)	GHRH + pyridostigmine stimulation test; IGF-I levels	Peak GH significantly lower in patients and obese controls compared with short healthy controls; IGF-I levels lower in patients than in obese and short controls
Angulo <i>et al.</i> , 1996 (71)	44 (2–16), 33 were obese	Insulin tolerance test; clonidine stimulation and L-dopa stimulation tests; GHD = peak GH < 10 $\mu\text{g/liter}$	GHD by at least two stimulation tests in 40/44 (91%) including 10 nonobese patients
Eiholzer <i>et al.</i> , 1998 (49)	19 (0.5–14.6)	IGF-I levels	IGF-I SD score $-0.7 \pm 0.8$
Grosso <i>et al.</i> , 1998 (72)	5 (8–11)	Insulin tolerance and clonidine stimulation tests; nocturnal GH secretion	GH peak < 10 $\mu\text{g/liter}$ in response to clonidine and insulin in 3/5; GH secretion below normal in 3/5
Grugni <i>et al.</i> , 1998 (73)	22 (13–30); 21 obese controls; 8 short healthy controls	GHRH + pyridostigmine stimulation test; 24-h GH secretion; IGF-I levels	Peak GH and mean spontaneous GH secretion were significantly lower in patients compared with short healthy controls and obese controls. IGF-I levels lower in patients than in the controls
Lindgren <i>et al.</i> , 1998 (74)	29 (3–12) 10 obese controls	24-h GH secretion; IGF-I levels	Mean GH 0.7 $\mu\text{g/liter}$ in patients and controls; IGF-I SD score $-1.5$ in patients and $-0.2$ in obese controls
Sipilä <i>et al.</i> , 1998 (75)	19 children	Clonidine stimulation test	Mean peak GH 3.28 mU/liter; 17/20 (85%) were considered to have severe GHD
Thacker <i>et al.</i> , 1998 (76)	16 (2–14)	Arginine and L-dopa stimulation tests in 14; clonidine and L-dopa tests in 1; clonidine test in 1; IGF-I levels in 11	Peak GH < 10 $\mu\text{g/liter}$ ; in response to arginine in 10/14 (71%); L-dopa in 12/15 (80%) and clonidine in 2/2
Carrel <i>et al.</i> , 1999 (60)	53 (4–16)	Clonidine stimulation test	Reduced GH secretion in all patients; mean peak GH, 2.0 $\mu\text{g/liter}$
Corrias <i>et al.</i> , 2000 (77)	43 (3–22), 7 were of normal weight; 24 obese controls; 25 short healthy controls	Clonidine, GHRH + arginine and GHRH + pyridostigmine stimulation tests; IGF-I levels	Peak GH levels were lower in patients, including those of normal weight, than in short healthy controls. IGF-I levels were lower in patients, regardless of weight, than in short healthy controls
Grugni <i>et al.</i> , 2001 (78)	16 (12.7–38.3); 15 obese individuals (12.9–42.9); 8 short healthy children (10.2–14.3)	GH-releasing peptide 6; GHRH + pyridostigmine; IGF-I levels	Peak GH and area under the curve lower in patients with Prader-Willi syndrome than in the control groups for both stimulation tests. IGF-I levels were low in all patients with Prader-Willi syndrome

reduced in size and there were fewer oxytocin-expressing neurons. In a later publication, Swaab (92) identified further irregularities associated with the syndrome. These included a 30% reduction in GHRH-releasing neurons in the nucleus arcuatus, a down-regulation of neuropeptide Y, and a deficiency in vasopressin. Magnetic resonance imaging has also revealed an abnormal bright spot in the posterior pituitary lobe of some affected individuals, which is considered to be a sign of hypothalamic dysfunction (93), and pituitary hypoplasia is frequently observed (94).

### III. The Hypothalamic-Pituitary-Gonadal Axis and Sexual Development in Prader-Willi Syndrome

In addition to insufficient GH secretion, the majority of individuals with Prader-Willi syndrome have a dysfunctional hypothalamic-pituitary-gonadal axis, which manifests as retarded or incomplete sexual development. Neonatal hypogonadism is difficult to assess in girls, but boys affected by Prader-Willi syndrome often have small penises and/or undescended testicles, both of which are indications of pre-

natal hypogonadotropic hypogonadism (9). Detailed studies of gonadal structure and function in neonatal and prepubertal patients with Prader-Willi syndrome are lacking.

Puberty is generally delayed in children with Prader-Willi syndrome, and in some individuals it may never occur at all (44, 48), although there have been at least two reported cases of precocious puberty (95, 96). In fact, many children experience premature adrenarche characterized by growth of axillary and pubic hair, this being particularly common in obese individuals (97). In many affected individuals, puberty fails to progress beyond this stage. For example, Greenswag (20) studied a group of 81 females with Prader-Willi syndrome between the ages of 10 and 28 yr. During the study period only 39% of these patients experienced menarche. It seems that very obese girls with Prader-Willi syndrome may be more likely to experience puberty. A possible explanation for this is that aromatization of androgens in the fat tissue of these patients produces sufficient amounts of estrogen to prompt maturation (9). However, even if menses do occur, bleeding is usually irregular, and it is unlikely to be associated with a normal menstrual cycle. Furthermore, spontaneous breast development is difficult to assess in Prader-Willi syndrome because normal glandular development may be confused with increasing fat tissue, particularly in obese girls. Pubertal growth spurt and bone maturation are also compromised in Prader-Willi syndrome. Reduced levels of circulating sex hormones fail to provide the trigger for GH secretion, which may itself be depressed (see *Section II*).

Hypogonadism associated with Prader-Willi syndrome is generally due to insufficient gonadotropin secretion, *i.e.*, hypogonadotropic hypogonadism. In confirmation of this diagnosis, investigators have found that most affected individuals demonstrate a poor response to GnRH (98, 99) that improves after prolonged clomiphene administration. Tolis *et al.* (100) have also observed that repeated administration of GnRH improves LH secretion. These findings point to a hypothalamic dysfunction in the regulation of gonadotropin secretion. However, it should be noted that some individuals showed a normal gonadotropin response to GnRH and that, in our own observations, some males have reached T levels within the normal range.

Wannarachue and Ruvalcaba (101) have also observed patients whose hypogonadism was not classically hypogonadotropic in nature. Of nine females, aged 11–44 yr, only one woman showed a normal LH response to clomiphene administration. Of the two men (age 23 and 28 yr), both had very small testes and elevated LH levels that responded poorly to clomiphene (FSH levels were not reported). The men also had low basal T levels that showed a significant but subnormal response to administration of human CG over 5 d. One of the men had undergone testicular biopsy of both a scrotal and a cryptorchid testis at the age of 15 yr. The microscopic picture was similar in the two biopsies: few germ cells, some thickening of the tubular basement membranes, and seemingly normal Leydig cells. The other man was biopsied at 28 yr of age; atrophy of seminiferous tubules with some hyalinization, thickened basement membranes, and clearly distinguishable Leydig cells were found. In another report of testicular histology, an 8-yr-old boy was

found to have no spermatogonia in his cryptorchid testes (102).

These scattered observations in male patients with Prader-Willi syndrome may be the result of hypogonadotropic hypogonadism combined with primary testicular dysgenesis manifesting as very poor spermatogenesis (98). Gonadotropin secretion may improve in early adulthood, leading to atrophy and hyalinization of seminiferous tubules. Furthermore, some male patients have poor Leydig cell function. Hypothetically, in the early years of life, this could be explained by a lack of LH stimulation, but in later years it may be secondary to seminiferous tubular damage caused by present or previous cryptorchidism.

Until recently it was thought that all individuals with Prader-Willi syndrome were sterile. However, we are now aware of two women with Prader-Willi syndrome who have become pregnant (103, 104). In one case, a woman with maternal disomy gave birth to a healthy girl, whereas the other woman, who had a deletion of 15q11-q13, gave birth to a child with Angelman syndrome.

It is possible that the tempo of gonadal maturation varies between individuals, thereby increasing the heterogeneity of patient groups in the various studies. There is some evidence for delayed gonadal maturation, as the normalization of T levels in blood in affected men over the age of 20 yr has been observed (our personal observations). Furthermore, one affected woman, reported to have given birth at the age of 33 yr, had primary amenorrhea until the age of 29 yr (103).

The variation in hypogonadism between individuals with Prader-Willi syndrome remains to be explained.

#### IV. The Status of Other Hormonal Axes in Prader-Willi Syndrome

Thyroid hormones and baseline TSH levels are normal or slightly elevated (9, 99, 100) in affected patients, although clinically significant thyroid dysfunction has not been documented in Prader-Willi syndrome. Spontaneous cortisol and ACTH levels are usually normal, as is the response to iv ACTH (9, 44, 99), although some authors have reported a subnormal adrenal response to ACTH (105). Basal and TRH-stimulated PRL levels are also within the normal range (99, 100). It has been reported that levels of both dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) are elevated in Prader-Willi syndrome (106, 107). In our own unpublished investigations of children aged 3–12 yr, 11 of 23 individuals had elevated levels of DHEAS when compared with the normal range. The three oldest children (11–12 yr of age) had pubic hair growth that was appropriate for their age (stage 2 to 3), while the remaining children with elevated DHEAS levels ( $n = 8$ ) had a BMI above 2 SD scores but no pubertal signs.

#### V. Endocrine Treatment of Patients with Prader-Willi Syndrome

Currently, there is no cure for Prader-Willi syndrome, but several of the problems associated with the condition can be managed effectively if treatment begins early. This is now

possible with the advent of molecular genetic methods that allow identification of affected children in the neonatal period. If the quality of life of patients with Prader-Willi syndrome is to be improved, a holistic approach to their treatment is needed. Before discussing the potential for endocrine hormone replacement, we describe some of the other therapies that may be required for successful management of the condition.

First, enteral gastric tube feeding is indicated in many neonates with Prader-Willi syndrome. Feeding difficulties commonly occur and may lead to malnutrition if not addressed. Training of balance and motor abilities is also important from an early age, as is physical training to increase muscle strength and energy consumption later in life. Other conditions, such as scoliosis, hyperopia/myopia, and cryptorchidism, should be treated if present. The behavior of affected children may be improved by imposition of regular routines and the strict reinforcement of behavioral limits. Affected children may also benefit from special education. However, the most important aspect of treating Prader-Willi syndrome is control of excessive weight gain, specifically with respect to fat. As we have previously indicated, individuals afflicted by this condition seem to have complications similar to those experienced by healthy obese people. Thus, weight reduction could be expected to have beneficial effects on morbidity and mortality. A strictly controlled diet, in conjunction with eating-habit training and regular exercise, is important from an early age and remains the basis for all therapeutic interventions. It has been noted, however, that early dietary intervention may reduce growth rate (108), possibly by unmasking GHD. To date, appetite suppressants have been mostly unsuccessful in controlling weight gain, as have surgical procedures such as gastric banding, small-intestine bypass, and jaw wiring (9). The various components of medical, psychological, and sociological care required by individuals with Prader-Willi syndrome have been extensively reviewed by Greenswag and Alexander (109).

#### A. Effects of GH treatment on stature

The GH-deficient state commonly associated with Prader-Willi syndrome, as evidenced by reduced GH secretion, low serum IGF-I levels, and clinical features typical of GHD, has provided a rationale for trials assessing the efficacy of GH treatment. From the current literature, more than 200 chil-

dren with Prader-Willi syndrome have received GH treatment. The duration of treatment has generally ranged between 6 and 36 months, although some children have received GH for longer periods. To date, three randomized controlled studies have been reported (60, 110, 111).

Longitudinal growth was increased by GH treatment in all studies. A summary of several studies that highlights the change in height SD scores during the first year of treatment is shown in Table 3 (60, 71, 75, 94, 110–113). Initial positive effects on growth velocity appear to be sustained throughout the second year of treatment (Fig. 3). Furthermore, a report involving children treated with GH over a period of 5 yr shows that growth continues to improve with the result that target height SD scores can be reached (114). Long-term efficacy has also recently been reported by Eiholzer and l'Allemand (115) in a study involving 4 yr of treatment.

#### B. Effects of GH treatment on body composition and muscle function

The effect of GH treatment on body composition in Prader-Willi syndrome has been assessed in several studies (28, 71, 75, 76, 112, 113), two of which were controlled (60, 110) (Table 4). In most of these studies, a controlled diet was initiated before commencement of GH therapy and maintained throughout the trial. The results show that GH treatment leads to an overall improvement in body composition by reducing fat mass and increasing muscle mass (Figs. 4 and 5). A report published at the time of writing supports these data (116). Two years of GH treatment led to a reduction in fat mass and a sustained increase in LBM. Data on the long-term effects of GH on body composition are, however, limited, and recent results show that 5 yr of GH treatment may still be insufficient to normalize LBM (117). Data from other long-term studies do suggest that GH treatment can help to stabilize BMI (114, 118). Improved motor performance and agility have also been documented in children with Prader-Willi syndrome who received GH (60, 113, 116). Furthermore, some reports suggest that such treatment has beneficial effects on physical appearance, energy, and endurance, thus improving the psychosocial functioning of affected children (70, 76, 112, 113). In a note of caution, it is recognized that many of these observations are based on spontaneous reports by parents and attending physicians; therefore, further studies are required to confirm these particular benefits.

TABLE 3. Summary of studies describing the effects of GH treatment on linear growth during the first year of treatment in children with Prader-Willi syndrome

Authors, year (ref.)	No. of patients (age in years)	Dose of GH quoted (dose in mg/kg/d)	Δ Height SD-score
Angulo <i>et al.</i> , 1996 (71)	30 (2–16)	0.2–0.3 mg/kg divided into 3 or 5 doses/wk	1.4 <sup>a</sup>
Hauffa 1997 (111)	16 (3–12)	0.15 IU/kg/d (0.05)	1.0
Lindgren <i>et al.</i> , 1997 (110)	15 (3–12)	0.1 IU/kg/d (0.03)	1.2
	12 (3–12)	0.2 IU/kg/d (0.07)	1.5
Davies <i>et al.</i> , 1998 (112)	25 (4–10)	20 IU/m <sup>2</sup> /wk (0.03)	0.6
Eiholzer <i>et al.</i> , 1998 (113)	12 (0.6–14.6)	24 IU/m <sup>2</sup> /wk (0.04)	0.4–1.2
Sipilä <i>et al.</i> , 1998 (75)	19	0.1 IU/kg/d (0.03)	1.2
Carrel <i>et al.</i> , 1999 (60)	35 (4–16)	1 mg/m <sup>2</sup> /d (0.03)	0.5
Schmidt <i>et al.</i> , 2000 (94)	9 (7–16)	14 IU/m <sup>2</sup> /wk (0.02)	1.2

<sup>a</sup> 24 months reported.




FIG. 3. The effect of GH treatment on height SD score. Group A comprises 15 children with Prader-Willi syndrome treated with GH, 0.1 IU/kg/d (0.33 mg/kg/d) for 2 yr; group B, 12 children with Prader-Willi syndrome who served as a control group during the first year and then were treated with GH, 0.2 IU/kg/d (0.66 mg/kg/d) during the second year of the study. Values are means  $\pm$  SEM. [Derived from Ref. 110.]

### C. Other effects of GH treatment

Two recent studies suggest that GH treatment can improve respiratory function in children with Prader-Willi syndrome. The first study, by Carrel and co-workers (60), showed that such therapy can improve respiratory muscle strength. In the second study, nine children with Prader-Willi syndrome received GH treatment for a period of 6 months (65). Both ventilation and the sensitivity of peripheral chemoreceptors to carbon dioxide increased during the trial, suggesting that GH exerts a direct or indirect effect on the central respiratory regulatory system.

### D. Side effects of GH treatment

The reported adverse events during GH treatment of patients with Prader-Willi syndrome are generally similar to those observed during treatment of children with classic GHD, Turner syndrome, or chronic renal insufficiency. Recent studies have shown that insulin levels in children with Prader-Willi syndrome are lower than in obese controls at baseline but increase during GH treatment. Glucose levels tend to remain unchanged or increase within the normal reference range (50, 60). However, considering the limited experience of prolonged GH treatment in these patients and the increased incidence of diabetes mellitus associated with the condition, carbohydrate metabolism (glucose, HbA<sub>1c</sub>) should be closely monitored in patients receiving GH.

Scoliosis, attributed to a combination of obesity and muscular hypotonia, is common in both children and adolescents with Prader-Willi syndrome. The rapid growth associated with GH may aggravate this spinal deformity; therefore, the

occurrence and development of scoliosis should be monitored during therapy. If quantification of scoliosis is difficult, *e.g.*, in advanced obesity, x-ray monitoring should be used. In a controlled, randomized study by Carrel *et al.* (60), 70% of the patients had a mild scoliosis ( $<20^\circ$ ) that occurred equally between the control and treatment groups. Furthermore, there was no significant worsening of the condition in either group during the 12 months of the study. In a similar study conducted over 1 yr by Lindgren *et al.* (74), no patient in either the control or GH-treated group experienced progression of scoliosis to the severe stage ( $>20^\circ$ ).

### E. Sex hormone replacement therapy

Treatment of hypothalamic-pituitary-gonadal failure in Prader-Willi syndrome remains a controversial issue, and the reader is therefore referred to an in-depth discussion by Lee (44). Most clinicians, however, agree that cryptorchidism should be corrected to enable detection of testicular malignancies (fertility may not be a goal in Prader-Willi syndrome). Yet, in one survey of 99 affected men with cryptorchidism, only 69 (70%) had undergone corrective surgery (20). The true incidence of hypogonadism in adults with Prader-Willi syndrome is unknown but in the same investigation only 41% of males and 18% of females received sex hormone replacement therapy. Sex hormone replacement therapy may be beneficial to hypogonadic patients in a number of ways. Obviously, the development of secondary sexual characteristics would be encouraged, but there is also potential for improvements in bone mineral content and bone mineral density. Possibly as a result of decreased estrogen and androgen production, these parameters are abnormally low in patients with Prader-Willi syndrome from a relatively early age (15, 119).

We have been unable to identify any systematic studies of sex hormone replacement therapy in adolescents or adults with Prader-Willi syndrome. Until such studies are published, these patients should be treated as other hypogonadal individuals. Thus, we suggest that if hypogonadism prevails to the age of 17–18 yr in a man with Prader-Willi syndrome, low doses of T substitution should be offered. Its subsequent effect on activity, strength, endurance, and quality of life should then be followed. If aggressiveness increases, the substitution could be stopped. In female patients, bone mineral density should be monitored during and after adolescence, and estrogen therapy should be considered if it becomes low-normal. In very obese patients, peripheral conversion of adrenal androgens to estrogen might suffice for the basic needs. However, in the increasing number of lean adolescent and adult patients with this syndrome, the estrogen status should be monitored yearly. The need of substitution therapy should be judged individually against the background of the development of bone mineral density, general activity, and quality of life. Given the recent reports of pregnancy in two women with Prader-Willi syndrome, caregivers should be aware of the possible need for contraceptives.

TABLE 4. Summary of studies describing the effects of GH treatment on body composition and muscle function in children with Prader-Willi syndrome

Authors, year (ref.)	No. of patients (age in years)	Dose of GH quoted (dose in mg/kg/d)	Results
Lee <i>et al.</i> , 1993 (29)	5 (5.4-13.0)	(0.05)	Total body fat decreased (mean 18%) and LBM increased (12.8-24.3%) significantly in 3 patients after 12 months' GH
Angulo <i>et al.</i> , 1996 (71)	30 (2-16)	0.2-0.3 mg/kg divided into 3 or 5 doses/wk	Significant decrease in weight SD score from 3.5 to 2.4 after 2 yr GH
Lindgren <i>et al.</i> , 1997 (110)	15 (3-12)	0.1 IU/kg/d (0.03)	Percent body fat decreased by 25% and muscle area of thigh increased significantly after 12 months' GH
	12 (3-12)	0.2 IU/kg/d (0.07)	Percent body fat decreased by 30% and muscle area of thigh increased significantly after 12 months' GH
Davies <i>et al.</i> , 1998 (112)	25 (4-10)	20 IU/m <sup>2</sup> /wk (0.03)	Significant decrease in fat mass and increase in LBM (mean, 4 kg) after 6 months GH. Children with the greatest percent body fat benefited the most. Several parents reported greater energy and activity in their children
Eiholzer <i>et al.</i> , 1998 (113)	12 (0.6-14.6)	24 IU/m <sup>2</sup> /wk (0.04)	Weight for height was reduced in obese patients and increased in younger underweight patients after 12 months' GH. Physical performance improved in a subset of patients
Sipilä <i>et al.</i> , 1998 (75)	19	0.1 IU/kg/d (0.03)	Weight for height and total body fat decreased after 12 months' GH
Thacker <i>et al.</i> , 1998 (76)	7 (5-14)	0.3 mg/kg/wk (0.04)	Many parents noted improved muscle mass and exercise tolerance in their children after 6 months' GH
Carrel <i>et al.</i> , 1999 (60)	35 (4-16)	1 mg/m <sup>2</sup> /d (0.03)	Significant decrease in fat mass (mean, 8%) and increase in LBM (mean, 5 kg) after 12 months' GH. Improvements also in respiratory muscle strength, physical strength and agility




FIG. 4. The effect of GH treatment on muscle area of the thigh. Group A comprises 10 children with Prader-Willi syndrome treated with GH, 0.1 IU/kg/d (0.33 mg/kg/d) for 2 yr; group B, 9 children with Prader-Willi syndrome who served as a control group during the first year and then were treated with GH, 0.2 IU/kg/d (0.66 mg/kg/d) during the second year of the study. Values are means  $\pm$  SEM. [Derived from Ref. 110.]

## VI. Summary

Prader-Willi syndrome is a disabling condition associated with dysfunction of the hypothalamic-pituitary axis. It is characterized by impaired GH secretion and hypogonadism. Those afflicted by the condition exhibit distinctive abnor-




FIG. 5. The effect of GH treatment on the ratio of lean mass to fat mass. Group A comprises 12 children with Prader-Willi syndrome treated with GH, 0.1 IU/kg/d (0.33 mg/kg/d) for 2 yr; group B, 11 children with Prader-Willi syndrome who served as a control group during the first year and then were treated with GH, 0.2 IU/kg/d (0.66 mg/kg/d) during the second year of the study. Values are means  $\pm$  SEM.

malities on chromosome 15, but the link between these and endocrine dysfunction remains unknown.

A growing number of reports describe the use of GH replacement therapy in children with Prader-Willi syndrome. Early studies focused on the beneficial effects of this

treatment on growth. However, it is now clear that GH treatment, when coupled with a strictly controlled diet, may help to reduce obesity and increase muscle mass. As the ultimate goal in the treatment of Prader-Willi syndrome is to reduce future morbidity and mortality, the observed improvement in body composition is, in our opinion, the main reason to use GH treatment in this group of patients. Furthermore, there is some evidence to suggest that GH treatment is associated with improved physical activity and agility in children with Prader-Willi syndrome, and published data suggest that there are few safety risks associated with GH treatment in these patients. Long-term safety studies are required, however, particularly regarding the effects of GH treatment on glucose metabolism and scoliosis.

At present, there are few reports in the literature regarding the use of sex hormone replacement therapy in affected individuals, although it is likely that such treatment would be beneficial in improving secondary sexual characteristics and helping to prevent osteoporosis.

In conclusion, Prader-Willi syndrome is associated with endocrine disorders that are often untreated. It is likely that a more active approach to correction of these hormone deficiencies would benefit individuals with this condition.

### Acknowledgments

Address all correspondence and requests for reprints to: Pia Burman, M.D., Ph.D., Pharmacia Corporation, Lindhagensgatan 126, SE-112 87 Stockholm, Sweden. E-mail: pia.burman@eu.pnu.com

### References

- Prader A, Labhart A, Willi H 1956 Ein syndrome von adipositas, kleinwuchs, kryptorchismus und oligophrenie nach myotonieartigem zustand im neugeborenenalter. *Schweiz Med Wochenschr* 86:1260–1261
- Prader A, Labhart A, Willi H 1961 Das syndrom von Imbezilliat, Adipositas Muskelhypotonie, Hypogenitalismus und Diabetes mellitus mit "myatonic"-Anamnese. In: *Proceedings of Second International Congress on Mental Retardation*. Vienna: S Karger
- Wharton RH, Loechner KJ 1996 Genetic and clinical advances in Prader-Willi Syndrome. *Curr Opin Pediatr* 8:618–624
- Cassidy SB 1997 Prader-Willi Syndrome. *J Med Genet* 34:917–923
- Nicholls RD, Ohta T, Gray TA 1999 Genetic abnormalities in Prader-Willi syndrome and lessons from mouse models. *Acta Paediatr Suppl* 88:99–104
- Nicholls RD, Saitoh S, Horsthemke B 1998 Imprinting in Prader-Willi and Angelman syndromes. *Trends Genet* 14:194–200
- Cassidy SB 1984 Prader-Willi syndrome. *Curr Probl Pediatr* 14: 1–55
- Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F 1993 Prader-Willi syndrome. Consensus diagnostic criteria. *Pediatrics* 91:398–402
- Bray GA, Dahms WT, Swerdloff RS, Fiser RH, Atkinson RL, Carrel RE 1983 The Prader-Willi syndrome. A study of 40 patients and a review of the literature. *Medicine* 62:59–80
- Burd L, Vesely B, Martsolf J, Kerbeshian J 1990 Prevalence study of Prader-Willi syndrome in North Dakota. *Am J Med Genet* 37: 97–99
- Ehara H, Ohno K, Takeshita K 1995 Frequency of the Prader-Willi syndrome in the San-in district, Japan. *Brain Dev* 17:324–326
- Gillessen-Kaesbach G, Gross S, Kaya-Westerloh S, Passarge E, Horsthemke B 1995 DNA methylation based testing of 450 patients suspected of having Prader-Willi syndrome. *J Med Genet* 32:88–92
- Horsthemke B, Dittrich B, Buiting K 1997 Imprinting mutations on human chromosome 15. *Hum Mutat* 10:329–337
- Laurance BM 1993 Prader-Willi syndrome. *Pediatric Res Commun* 7:77–91
- Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, Chiumello G 1997 Peculiar body composition in patients with Prader-Labhart-Willi syndrome. *Am J Clin Nutr* 65:1369–1374
- Wollmann HA, Schultz U, Grauer ML, Ranke MB 1998 Reference values for height and weight in Prader-Willi syndrome based on 315 patients. *Eur J Pediatr* 157:634–642
- Hall DM, Smith DW 1972 Prader-Willi syndrome. *J Pediatr* 81: 286–293
- Schoeller DA, Levitsky LL, Bandibi LG, Dietz WW, Walczak A 1988 Energy expenditure and body composition in Prader-Willi syndrome. *Metabolism* 37:115–120
- Meaney FJ, Butler MG 1989 Assessment of body composition in Prader-Lubhart-Willi syndrome. *Clin Genet* 35:300 (Abstract)
- Greenswag L 1987 Adults with Prader-Willi syndrome. A survey of 232 cases. *Dev Med Child Neurol* 29:145–152
- Laurance BM, Brito A, Wilkinson J 1981 Prader-Willi syndrome after the age of 15 years. *Arch Dis Child* 56:181–186
- Butler MG, Meaney FJ 1991 Standards for selected anthropometric measurements in Prader-Willi syndrome. *Pediatrics* 88:853–860
- Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T 2000 Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. *Acta Paediatr* 89:1302–1311
- Nagai T, Matsuo N, Kayanuma Y, Tonoki H, Fukushima Y, Ohashi H, Murai T, Hasegawa T, Kuroki Y, Niikawa N 2000 Standard growth curves for Japanese patients with Prader-Willi syndrome. *Am J Med Genet* 95:130–134
- Dykens EM, Cassidy SB 1996 Prader-Willi syndrome. Genetic, behavioral, and treatment issues. *Child Adolesc Psychiatr Clin North Am* 5:913–927
- Curfs LMG, Fryns J-P 1992 Prader-Willi syndrome: a review with special attention to cognitive and behavioral profile. *Birth Defects* 28:99–104
- Davies PSW, Joughin C 1992 Assessment of body composition in the Prader-Willi syndrome using bioelectrical impedance. *Am J Med Genet* 44:75–78
- Davies PSW, Joughin C 1993 Using stable isotopes to assess reduced physical activity of individuals with Prader-Willi syndrome. *Am J Ment Retard* 3:349–353
- Lee PD, Hwu K, Henson H, Brown BT, Bricker JT, LeBlanc AD, Fiorotto ML, Greenberg F, Klish WJ 1993 Body composition studies in Prader-Willi syndrome: effects of growth hormone therapy. *Basic Life Sci* 60:201–205
- Boot AM, Bouquet J, de Ridder MAJ, Krenning EP, de Muinck Keizer-Schrama SMPF 1997 Determinants of body composition measured by dual-energy x-ray absorptiometry in Dutch children and adolescents. *Am J Clin Nutr* 66:232–238
- Ogle GD, Allen JR, Humphries IR, Lu PW, Briody JN, Morley K, Howman-Giles R, Cowell CT 1995 Body composition assessment by dual-energy x-ray absorptiometry in subjects aged 4–26. *Am J Clin Nutr* 61:746–753
- Eiholzer U, Blum WF, Molinari L 1999 Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome. *J Pediatr* 134:222–225
- Nardella MT, Sulzbacher SI, Worthington-Roberts BS 1983 Activity levels of persons with Prader-Willi syndrome. *Am J Ment Defic* 87:498–505
- Coplin SS, Hine J, Gormican A 1976 Outpatient dietary management in the Prader-Willi syndrome. *J Am Diet Assoc* 68:330–334
- Nelson RA, Anderson LF, Gastineau CF, Hayles AB, Stamnes CL 1973 Physiology and natural history of obesity. *JAMA* 223:627–630
- van Mil EG, Westerterp KR, Kester AD, Curfs LM, Gerver WJ, Schrandt-Stumpel CT, Saris WH 2000 Activity related energy expenditure in children and adolescents with Prader-Willi syndrome. *Int J Obes Relat Metab Disord* 24:429–434
- van Mil EG, Westerterp KR, Gerver WJ, Curfs LM, Schrandt-Stumpel CT, Kester AD, Saris WH 2000 Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition. *Am J Clin Nutr* 71:752–756

38. **Klish WJ** 1995 Childhood obesity: pathophysiology and treatment. *Acta Paediatr Jpn* 37:1–5
39. **Rosengren A, Wedel H, Wilhelmsen L** 1999 Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study. *Eur Heart J* 20:269–277
40. **Csabi G, Torok K, Jeges S, Molnar D** 2000 Presence of metabolic cardiovascular syndrome in obese children. *Eur J Pediatr* 159:91–94
41. **Karason K, Lindroos AK, Stenlof K, Sjostrom L** 2000 Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. *Arch Intern Med* 160:1797–1802
42. **National Task Force on the Prevention and Treatment of Obesity** 2000 Overweight, obesity and health risk. *Arch Intern Med* 160: 898–904
43. **Holm VA, Launen EL** 1981 Prader-Willi syndrome and scoliosis. *Dev Med Child Neurol* 23:192–201
44. **Lee PDK** 1995 Endocrine and metabolic aspects of Prader-Willi syndrome. In: Greenswag LR, Alexander RC, eds. *Management of Prader-Willi syndrome*. New York: Springer-Verlag; 32–57
45. **Tze WJ, Dunn HG, Rothstein R** 1981 The endocrine profiles and metabolic aspects of Prader-Willi syndrome. In: Holm VA, Sulzbacher S, Pipes PL, eds. *Prader-Willi syndrome*. Baltimore, MD: University Park Press; 281–291
46. **Kousholt AM, Beck-Nielsen H, Lund HT** 1983 A reduced number of insulin receptors in patients with Prader-Willi syndrome. *Acta Endocrinol (Copenh)* 104:345–351
47. **Illig R, Tschumi A, Vischer D** 1975 Glucose intolerance and diabetes mellitus in patients with the Prader-Labhart-Willi syndrome. *Mod Probl Pediatr* 12:203–210
48. **Cassidy SB, Devi A, Mukaida C** 1994 Aging in Prader-Willi syndrome: 22 patients over age 30 years. *Proc Greenwood Genet Center* 13:102–103
49. **Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A** 1998 Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. *Eur J Pediatr* 157:890–893
50. **Lindgren AC, Hagenas L, Ritzén EM** 1999 Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin hemostasis. *Swedish National Growth Hormone Advisory Group. Horm Res* 51:157–161
51. **Zipf WB** 1999 Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. *Acta Paediatr Suppl* 433:115–117
52. **Schuster DP, Osei K, Zipf WB** 1996 Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. *Metabolism* 12:1514–1520
53. **Reed WB, Ragsdale W, Curtis AC, Rickards HJ** 1968 Acanthosis nigricans in association with various genodermatosis. *Acta Derm Venereol* 149:963–964
54. **Lamb AS, Johnson WM** 1987 Premature coronary artery atherosclerosis in a patient with Prader-Willi syndrome. *Am J Med Genet* 28:873–880
55. **Juul J, Dupont A** 1967 Prader-Willi syndrome. *J Ment Deficiency Res* 11:12–22
56. **Bassali R, Hoffman WH, Chen H, Tuck-Muller CM** 1997 Hyperlipidemia, insulin-dependent diabetes mellitus, and rapidly progressive diabetic retinopathy and neuropathy in Prader-Willi syndrome with del. (15) (q11.2q13). *Am J Med Genet* 71:267–270
57. **Laurance BM** 1967 Hypotonia, mental retardation, obesity, and cryptorchidism associated with dwarfism, and diabetes in children. *Arch Dis Child* 42:126–139
58. **Bier DM, Kaplan SL, Havel RJ** 1977 The Prader-Willi syndrome, regulation of fat transport. *Diabetes* 26:874–880
59. **Butler MG, Swift LL, Hill JO** 1990 Fasting plasma lipid, glucose, and insulin levels in Prader-Willi syndrome and obese individuals. *Dysmorphol Clin Genet* 4:23–26
60. **Carrel AL, Myers SE, Whitman BY, Allen DB** 1999 Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: a controlled study. *J Pediatr* 134:215–221
61. **l'Allemand D, Eiholzer U, Schlumpf M, Steinert H, Riesen W** 2000 Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome. *Eur J Pediatr* 159: 835–842
62. **Hakonarson H, Moskovitz J, Daigle KL, Cassidy SB, Cloutier MM** 1995 Pulmonary function abnormalities in Prader-Willi syndrome. *J Pediatr* 126:565–570
63. **Arens R, Gozal D, Burrell BC, Bailey SL, Bautista DB, Keens TG, Ward SL** 1996 Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome. *Am J Respir Crit Care Med* 153:283–287
64. **Schluter B, Buscbatz D, Trowitzsch E, Aksu F, Andler W** 1997 Respiratory control in children with Prader-Willi syndrome. *Eur J Pediatr* 156:65–68
65. **Lindgren AC, Hellström LG, Ritzén EM, Milerad J** 1999 Growth hormone treatment increases CO<sub>2</sub>-response, ventilation and central respiratory drive in children with Prader-Willi syndrome. *Eur J Pediatr* 158:936–940
66. **Fesseler WH, Bierich JR** 1983 Untersuchungen beim Prader-Labhart-Willi-syndrom. *Monatsschr Kinderheilkd* 131:844–847
67. **Costeff H, Holm VA, Ruvalcaba R, Shaver J** 1990 Growth hormone secretion in Prader-Willi syndrome. *Acta Paediatr Scand* 79:1059–1062
68. **Calisti L, Giannesi N, Cesaretti G, Saggese G** 1991 Studio endocrino nella sindrome di Prader-Willi. A proposito di 5 casi. *Minerva Pediatr* 43:587–593
69. **Huw K, Klish WJ, Henson H, Brown BT, Bricker JT, LeBlanc AD, Fiorotto ML, Greenberg F, Lee PDK** 1992 Endocrine status, growth hormone therapy and body composition in Prader-Willi syndrome. *Proc 74<sup>th</sup> Meeting of The Endocrine Society, San Antonio, TX, 1992*, p 229 (Abstract 710)
70. **Cappa M, Grossi A, Borrelli P, Ghigo E, Bellone J, Benedetti S, Carta D, Loche S** 1993 Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhardt-Willi syndrome. *Horm Res* 39: 51–55
71. **Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantonio M** 1996 Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. *J Pediatr Endocrinol Metab* 3:393–399
72. **Grosso S, Cioni M, Buoni S, Peruzzi L, Pucci L, Berardi R** 1998 Growth hormone secretion in Prader-Willi syndrome. *J Endocrinol Invest* 21:418–422
73. **Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F** 1998 Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine and administration in the Prader-Willi syndrome. *Clin Endocrinol (Oxf)* 48: 769–775
74. **Lindgren AC, Hagenas L, Müller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzén EM** 1998 Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. *Acta Paediatr* 87:28–31
75. **Sipilä I, Alanne S, Apajasalo M, Hietanen H** 1998 Growth hormone therapy in children with Prader-Willi syndrome. A preliminary report of one year treatment in 19 children. *Horm Res* 50(Suppl 3):24 (Abstract)
76. **Thacker MJ, Hainline B, St Dennis-Fezle L, Johnson NB, Pescovitz OH** 1998 Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency. *Horm Res* 49:216–220
77. **Corrias A, Bellone J, Beccaria L, Bosio L, Trifiro G, Livieri C, Ragusa L, Salvatoni A, Andreo M, Ciampalini P, Tonini G, Crino A** 2000 GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. *Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology. J Endocrinol Invest* 23:84–89
78. **Grugni G, Guzzaloni G, Morabito F** 2001 Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome. *J Endocrinol Invest* 24:340–348
79. **Williams T, Berelowitz M, Joffe SN, Thorner MO, Rivieer J, Vale W, Frohman LA** 1984 Impaired growth hormone responses to growth hormone-releasing factor in obesity: a pituitary defect reversed by weight reduction. *N Engl J Med* 311:1403–1407
80. **Scacchi M, Pincelli AI, Cavagnini F** 1999 Growth hormone in obesity. *Int J Obes Relat Metab Disord* 23:260–271

81. **Lanzi R, Luzi L, Caumo A, Andreotti AC, Manzoni MF, Malighetti ME, Sereni LP, Pontiroli AE** 1999 Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects. *Metabolism* 48:1152–1156
82. **Nam SY, Lee EJ, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB** 1997 Effect of obesity on total and free insulin-like growth factor (IGF)-I, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. *Int J Obes Relat Metab Disord* 21:355–359
83. **Park MJ, Kim HS, Kang JH, Kim DH, Chung CY** 1999 Serum levels of insulin-like growth factor (IGF)-I, free IGF-I, IGF binding protein (IGFBP)-I, IGFBP-3 and insulin in obese children. *J Pediatr Endocrinol Metab* 12:139–144
84. **Ghigo E, Mazza E, Corrias A, Imperiale E, Goffi S, Arvat E, Bellone J, De Sanctis C, Müller EE, Camanni F** 1989 Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. *Metabolism* 38:631–633
85. **Beccaria L, Benzi F, Sanzari A, Bosio L, Brambilla P, Ghiomello G** 1996 Impairment of GH responsiveness to GH releasing hormone and pyridostigmine in patients affected with Prader-Labhardt-Willi syndrome. *J Endocrinol Invest* 19:687–692
86. **Bideci A, Cinaz P, Hasanoglu A, Elbeg S** 1997 Serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in obese children. *J Pediatr Endocrinol Metab* 10:295–299
87. **Radetti G, Bozzola M, Pasquino B, Paganini C, Agliarolo A, Livieri C, Barreca A** 1998 Growth hormone bioactivity, insulin-like growth factors (IGFs) and IGF binding proteins in obese children. *Metabolism* 47:1490–1493
88. **Rosenbaum M, Gerner J, Leibel R** 1989 Effects of systemic (GH) administration on regional adipose tissue distribution in GH deficient children. *J Clin Endocrinol Metab* 69:1274–1281
89. **Vignolo M, Naselli A, Di Battista E, Mostert M, Aicardi G** 1988 Growth and development in simple obesity. *Eur J Pediatr* 147:242–244
90. **Vanderschueren-Lodeweycks M** 1993 The effect of simple obesity on growth and growth hormone. *Horm Res* 40:23–30
91. **Swaab DF, Purba JS, Hofman MA** 1995 Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome. A study of five cases. *J Clin Endocrinol Metab* 80:573–579
92. **Swaab DF** 1997 Prader-Willi syndrome and the hypothalamus. *Acta Paediatr Suppl* 423:50–54
93. **Miller L, Angulo M, Price D, Taneja S** 1996 MR of the pituitary in patients with Prader-Willi syndrome: size determinations and imaging findings. *Pediatr Radiol* 26:43–47
94. **Schmidt H, Bechtold S, Schwarz HP** 2000 Prader-Labhart-Willi syndrome: auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency. *Eur J Med Res* 5:307–310
95. **Kauli R, Prager-Lewin R, Laron Z** 1978 Pubertal development in the Prader-Labhart-Willi syndrome. *Acta Paediatr Scand* 67:763–767
96. **Vanelli MD, Bernasconi S, Caronna N, Viridis R, Terzi C, Giovanelli G** 1984 Precocious puberty in a male with Prader-Labhart-Willi syndrome. *Helv Paediatr Acta* 39:373–377
97. **Garty B, Shuper A, Mimouni M, Varsano I, Kauli R** 1982 Primary gonadal failure and precocious adrenarche in a boy with Prader-Labhart-Willi syndrome. *Eur J Pediatr* 139:201–203
98. **Jeffcoate WJ, Laurance BM, Edwards CRW, Besser GM** 1980 Endocrine function in the Prader-Willi syndrome. *Clin Endocrinol (Oxf)* 12:81–89
99. **Ritzén EM, Bolme P, Hall K** 1992 Endocrine physiology and therapy in Prader-Willi syndrome. *NATO ASI Series H61*:153–169
100. **Tolis G, Lewis W, Verdy M, Friesen HG, Solomon S, Pagalis G, Pavlatos F, Fessas PH, Rochefort JG** 1974 Anterior pituitary function in the Prader-Labhart-Willi syndrome. *J Clin Endocrinol Metab* 39:1061–1066
101. **Wannarachue N, Ruvalcaba HA** 1975 Hypogonadism in Prader-Willi Syndrome. *Am J Ment Deficiency* 79:592–603
102. **Katcher ML, Bargman GJ, Gilert EF, Opitz JM** 1977 Absence of spermatogonia in the Prader-Willi syndrome. *Eur J Pediatr* 124:257–260
103. **Akefeldt A, Tornhage CJ, Gillberg C** 1999 A women with Prader-Willi syndrome gives birth to a healthy baby girl. *Dev Med Child Neurol* 41:789–790
104. **Schulze A, Mogensen H, Hamborg-Petersen B, Graem N, Østergaard J, Brøndum-Nielsen K** 2001 Fertility in Prader-Willi syndrome: a case report with Angelman syndrome in the offspring. *Acta Paediatr* 90:455–459
105. **Rudd BT, Chance GW, Theodoridis CG** 1969 Adrenal response to ACTH in patients with Prader-Willi syndrome, simple obesity, and constitutional dwarfism. *Arch Dis Child* 44:244–247
106. **Chasalow FI, Blethen SL, Tobash JG, Myles D, Butler MG** 1987 Steroid metabolic disturbances in Prader-Willi syndrome. *Am J Med Genet* 28:857–864
107. **Schmidt H, Schwarz HP** 2001 Premature adrenarche, increased growth velocity and accelerated bone age in male patients with Prader-Labhart-Willi syndrome. *Eur J Pediatr* 160:69–70
108. **Schmidt H, Schwarz HP, Enders A** 2001 Dietary intervention in the first four years prevents abnormal weight gain but negatively affects height development in Prader-Willi syndrome. *Acta Paediatr* 90:468–9
109. **Greenswag LR, Alexander RC** 1995 Management of Prader-Willi syndrome. 2<sup>nd</sup> ed. New York: Springer-Verlag
110. **Lindgren AC, Hagenäs L, Müller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzén EM** 1997 Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report. *Acta Paediatr Suppl* 423:60–62
111. **Hauffa BP** 1997 One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. *Acta Paediatr Suppl* 423:63–65
112. **Davies PSW, Evens S, Broomhead S, Clough H, Day JME, Laidlaw A, Barnes ND** 1998 Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome. *Arch Dis Child* 78:474–476
113. **Eiholzer U, Gisin R, Weinmann C, Kriemler S, Steinert H, Torresani T, Zachmann M, Prader A** 1998 Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. *Eur J Pediatr* 157:368–377
114. **Lindgren AC, Ritzén EM** 1999 Five years of growth hormone treatment in children with Prader-Willi syndrome. *Acta Paediatr Suppl* 433:109–111
115. **Eiholzer U, l'Allemand D** 2000 Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. *Horm Res* 53:185–192
116. **Myers SE, Carrel AL, Whitman BY, Allen DB** 2000 Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. *J Pediatr* 137:42–49
117. **Eiholzer U, l'Allemand D, van der Sluis I, Steinert H, Gasser T, Ellis K** 2000 Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy. *Horm Res* 53:200–206
118. **Tauber M, Barbeau C, Jouret B, Pienkowski C, Malzac P, Moncla A, Rochiccioli P** 2000 Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children. *Horm Res* 53:279–287
119. **Rubin K, Cassidy SB** 1988 Hypogonadism and osteoporosis. In: Greenswag LR, Alexander RC, eds. Management of Prader-Willi syndrome. New York: Springer-Verlag; 23–33